[go: up one dir, main page]

DE69018990D1 - Stabile interleukine enthaltende impfstoffzusammensetzungen. - Google Patents

Stabile interleukine enthaltende impfstoffzusammensetzungen.

Info

Publication number
DE69018990D1
DE69018990D1 DE69018990T DE69018990T DE69018990D1 DE 69018990 D1 DE69018990 D1 DE 69018990D1 DE 69018990 T DE69018990 T DE 69018990T DE 69018990 T DE69018990 T DE 69018990T DE 69018990 D1 DE69018990 D1 DE 69018990D1
Authority
DE
Germany
Prior art keywords
vaccine compositions
interleukine
stable
compositions containing
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69018990T
Other languages
English (en)
Other versions
DE69018990T2 (de
Inventor
Subramonia Pillai
Garvin Bixler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biologics Inc filed Critical Praxis Biologics Inc
Publication of DE69018990D1 publication Critical patent/DE69018990D1/de
Application granted granted Critical
Publication of DE69018990T2 publication Critical patent/DE69018990T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69018990T 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen. Expired - Fee Related DE69018990T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins

Publications (2)

Publication Number Publication Date
DE69018990D1 true DE69018990D1 (de) 1995-06-01
DE69018990T2 DE69018990T2 (de) 1995-12-14

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69018990T Expired - Fee Related DE69018990T2 (de) 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen.

Country Status (12)

Country Link
EP (1) EP0482076B1 (de)
JP (2) JP3485184B2 (de)
KR (1) KR0177179B1 (de)
AT (1) ATE121629T1 (de)
AU (1) AU648509B2 (de)
CA (1) CA2063587C (de)
DE (1) DE69018990T2 (de)
DK (1) DK0482076T3 (de)
ES (1) ES2075900T3 (de)
FI (1) FI104233B (de)
NO (1) NO301577B1 (de)
WO (1) WO1991001143A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484T4 (de) * 1989-10-27 1999-09-16 Arch Development Corp., Chicago Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
CA2098726A1 (en) * 1990-12-19 1992-06-20 Edward J. Rozhon Use of il-4 to enhance immune response to immunogens in vaccines
JPH07500813A (ja) * 1991-05-13 1995-01-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア リポソーム多糖体ワクチン
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO1996007102A1 (en) * 1994-09-01 1996-03-07 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
ES2262181T3 (es) * 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en) 1999-12-03 2001-06-12 Celltech Chiroscience Limited Interleukin-1 muteins useful as vaccine adjuvants
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007039583A1 (en) 2005-09-30 2007-04-12 Lipoxen Technologies Limited Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
AU2007260687B2 (en) 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
CN101622008A (zh) * 2007-03-09 2010-01-06 默克公司 乳头瘤病毒疫苗组合物
US10639367B2 (en) * 2012-11-02 2020-05-05 Cytuvax Composition comprising cytokine macro-aggregates
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
JP2022507606A (ja) 2018-11-16 2022-01-18 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
EP4100045A1 (de) 2020-02-05 2022-12-14 Washington University Verfahren zur behandlung eines festen tumors mit einer kombination aus einem il-7-protein und car-tragenden immunzellen
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
IL302482A (en) 2020-11-05 2023-06-01 Neoimmunetech Inc Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
CA2063587A1 (en) 1991-01-15
JP3485184B2 (ja) 2004-01-13
EP0482076A1 (de) 1992-04-29
NO920161L (no) 1992-03-05
AU6050090A (en) 1991-02-22
ES2075900T3 (es) 1995-10-16
CA2063587C (en) 2005-08-30
FI920132A0 (fi) 1992-01-13
FI104233B1 (fi) 1999-12-15
FI104233B (fi) 1999-12-15
KR920703103A (ko) 1992-12-17
ATE121629T1 (de) 1995-05-15
DK0482076T3 (da) 1995-07-17
JP2004002463A (ja) 2004-01-08
NO301577B1 (no) 1997-11-17
DE69018990T2 (de) 1995-12-14
AU648509B2 (en) 1994-04-28
JPH04506663A (ja) 1992-11-19
NO920161D0 (no) 1992-01-13
EP0482076B1 (de) 1995-04-26
WO1991001143A1 (en) 1991-02-07
KR0177179B1 (ko) 1999-03-20

Similar Documents

Publication Publication Date Title
DE69018990D1 (de) Stabile interleukine enthaltende impfstoffzusammensetzungen.
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
ES2092306T3 (es) Adyuvante para vacunas.
ES2186809T3 (es) Composiciones de vacunas para administracion intranasal, comprendiendo chitosana y su uso.
DK400181A (da) Sammensatte materialer indeholdende immobiliserede biologisk aktive arter fremgangsmaade til deres fremstilling samt deres anvendelse
MX9803290A (es) Composiciones de la vacuna influenza.
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
NO892169D0 (no) Zn-modifisert silika og fremgangsmaate for dets fremstilling.
ATE61937T1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
PT1053017E (pt) Vacinas compreendendo interleucina-12 e antigenio de virus herpes simplex
DK0884329T3 (da) Anti-idiotypisk antistof, som inducerer en immunreaktion mod et glycosphingolipid, samt anvendelse deraf
DK504389A (da) Adjuveret antigenoploesning, dens fremstilling samt zink- eller jernhydroxidgel til anvendelse derved
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
JPS55106261A (en) Composition made of dispersed body of colloid silica and colloid titania
ES2056378T3 (es) Procedimiento de extraccion.
FI971402A7 (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä s isältävien rokotteiden valmistamiseksi
FI924215A7 (fi) IL-4:n käyttö infektioosien antigeenisten aineiden aiheuttaman immuuni reaktion lisäämiseksi
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
FI843204A0 (fi) Renat, detoxifierat endotoxin.
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
IT8049346A0 (it) Composizione antigene relativo vaccino e procedimento di produzione
DK0570682T3 (da) Syntetiske lipid-A-glycoconjugat-antigener til anvendelse i vacciner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMERICAN CYANAMID CO., PORTLAND, ME., US

8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

8339 Ceased/non-payment of the annual fee